dialysis. Clin J Am Soc Nephrol. 2014;9:1813–21 [consultado 15 Dic 2016]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24832095

3. Gutiérrez-Sánchez D, Leiva-Santos JP, Sánchez-Hernández R, Hernández-Marrero D, Cuesta-Vargas AI. Spanish modified version of the palliative care outcome scale-symptoms renal: Cross-cultural adaptation and validation. BMC NephrolV 17. 2016:180 [consultado 12 Dic 2016]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27863475

4. Montañés Bermúdez R, Bover Sanjuán J, Oliver Samper A, Ballarín Castán JA, Gràcia García S. [Assessment of the new CKD-EPI equation to estimate the glomerular filtration rate]. Nefrologia. 2010;30:185–94 [consultado 2 Ene 2017]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20038962

5. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J MedV 108. 2000:609–13 [consultado 15 Nov 2016]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10856407

6. Brown MA, Crail SM, Masterson R, Foote C, Robins J, Katz I, et al. ANZSN renal supportive care 2013: Opinion pieces [corrected]. Nephrology (Carlton). 2013;18:401–54 [consultado 12 Nov 2016]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23586687

7. Arai Y, Kanda E, Kikuchi H, Yamamura C, Hirasawa S, Aki S, et al. Decreased mobility after starting dialysis is an independent risk factor for short-term mortality after initiation of dialysis. Nephrology (Carlton). 2014;19:227–33 [consultado 2 Feb 2017]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24397310

8. Maung SC, El Sara A, Chapman C, Cohen D, Cukor D. Sleep disorders and chronic kidney disease. World J Nephrol. 2016;5:224–32 [consultado 10 Ene 2017]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27152260

9. Lee A, Lambert K, Byrne P, Lonergan M. Prevalence of constipation in patients with advanced kidney disease. J Ren Care. 2016;42:144–9 [consultado 22 Ene 2017]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27113374

10. Molnar MZ, Novak M, Szeifert L, Ambrus C, Keszei A, Koczy A, et al. Restless legs syndrome, insomnia, and quality of life after renal transplantation. J Psychosom Res. 2007;63:591–7 [consultado 25 Jul 2017]. Disponible en: https://ncbi.nlm.nih.gov/pubmed/18061749/

Daniel Gutiérrez Sánchez [a,b], Juan P. Leiva-Santos [c], María José Macías López [d] y Antonio I. Cuesta-Vargas [b,*]

[a] Fundación Cudeca, Arroyo de la Miel, Málaga, España
[b] Departamento de Fisioterapia, Instituto de Investigación Biomédico de Málaga (IBIMA), Universidad de Málaga, Málaga, España
[c] Hospital de Manacor, Mallorca, Islas Baleares, España
[d] Servicio de Nefrología, Hospital Regional Universitario de Málaga, Málaga, España

* Autor para correspondencia.
Correo electrónico: acuesta@uma.es (A.I. Cuesta-Vargas).

Unmeasurable severe hypernatremia: A different way of using the calculated serum osmolality formula

Hipernatremia incalculable severa: una manera diferente de utilizar la fórmula de osmolaridad sérica

Dear Editor:

Hypernatremia is a common electrolyte disorder with increased morbidity and mortality, especially in elderly and critically ill patients. It is most frequently associated with free water losses, but it can also be induced by the administration of hypertonic saline or sodium bicarbonate.[1,2] The mortality rates for critically ill patients with hypernatremia are as high as 50%.[3] Symptoms from hypernatremia include lethargy, weakness, irritability, seizures, and are as severe as coma.[4,5]

A 59-year-old Caucasian female presented to the hospital with subarachnoid hemorrhage and severe intracranial hypertension (ICH). The patient required intubation for ventilator support, and started on vasopressors for hemodynamic support. She was also started on hypertonic (3%) saline as an adjunctive therapy for her ICH. On admission, her serum sodium was 141 mEq/l. Over the next 4 days, despite hypertonic saline having been discontinued, the patient developed severe hypernatremia that was undetectable by the standard assay (ion specific electrode). Her serum sodium was measured as >180 mEq/l. She also developed polyuria with a urine osmolality of 220 mOsm/l, raising the possibility of diabetes insipidus. D5W was started for this patient in combination with scheduled doses of DDAVP to decrease her serum sodium slowly. We had to use the equation (Fig. 1) for serum osmolality to calculate the serum sodium, given the significantly elevated levels, to ensure proper correction. We recognized that the equation is an indirect marker for serum sodium determination, which incorporates blood urea nitrogen and serum glucose concentrations in its calculation. Her peak serum osmolality was 403 mOsm/kg, and it was later lowered to 381 mOsm/kg in a 24-h interval (Table 1). It was not until 30 h into therapy that the serum sodium level became

$$Serum\ Osmolality\ (calculated) = 2\ [Na^+] + \frac{[BUN]}{2.8} + \frac{[Glucose]}{18}$$

With [Na+] unmeasurable, we isolated that variable and use the <u>measured</u> serum osmolality, assuming a negligible osmolar gap. We derived this equation to calculate the expected serum sodium concentration when it was unmeasurable :

$$Expected\ serum\ [Na^+] = \frac{\left[Serum\ osmolality\ (measured) - \frac{[BUN]}{2.8} - \frac{[Glucose]}{18}\right]}{2}$$

Fig. 1 – Serum osmolality calculator with algebraic modification.

Table 1 – Lab parameters during hospitalization.

Date	Serum osmolality	BUN	Glucose	Na$^+$ (measured)	Na$^+$ (calculated)
5/10/17	394	6	196	>180	191
5/10/17	403	5	220	>180	194
5/10/17	395	5	126	>180	194
5/10/17	387	6	169	>180	188
5/10/17	387	6	194	>180	187
5/11/17	381	8	197	>180	184

5/10/17 determinations made during 5 h intervals.

detectable at 173 mEq/l, with a concomitant serum osmolality of 366 mOsm/kg.

In conclusion, using the equation for serum osmolality is an indirect method to calculate the serum sodium level,[6] which was especially useful in this patient with severe hypernatremia that was unmeasurable (>180 mEq/l) with our standard assay. The applicability of the above mentioned formula allowed us to decreased the patients undetectable serum sodium close to normal range, preventing over-correction and under-correction.[7,8] We estimate that the patient's serum sodium could have been as high as 194 mEq/l.

Despite these limitations, we were able to indirectly monitor the patient's serum sodium level and adequately correct to goal.[9,10] The patient survived her hospitalization and was discharged to a rehabilitation unit with improved serum sodium levels.

BIBLIOGRAFÍA

1. Sterns RH. NEJM. 2015;372:55–65.
2. Adrogué HJ, Madias NE. Hypernatremia. NEJM. 2000;342:1493–9.
3. Lindner G, Funk G-C, Schwarz C, Kneidinger N, Keider A, Schneeweiss B, et al. Hypernatremia in the critically ill is an independent risk factor for mortality. AJKD. 2007;6:952–7.
4. Feig PU, McCurdy DK. The hypertonic state. N Engl J Med. 1977;297:1444–54.
5. Verbalis JG. Brain volume regulation in response to changes in osmolality. Neuroscience. 2010;168:862–70.
6. Edelman IS, Leibman J, O'Meara MP, Birkenfeld LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium, and total body water. J Clin Invest. 1958;37:1236–56.
7. Alshayeb HM, Showkat A, Babar F, Mangold T, Wall BM. Severe hypernatremia correction rate and mortality in hospitalized patients. Am J Med Sci. 2011;341:356–60.
8. Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med. 1986;81:1033–40.
9. Carlotti AP, Bohn D, Mallie JP, Halperin ML. Tonicity balance, and not electrolyte free water calculations, more accurately guides therapy for acute changes in natremia. Intensive Care Med. 2001;27:921–4.
10. Lien YH, Saphiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest. 1990;85:1427–35.

Aravindhan Arumugarajah, Christopher Webster, Luis M. Ortega *

Allegheny General Hospital, Division of Nephrology and Hypertension, 320 East North Avenue, Pittsburgh, PA 15212, United States

* Corresponding author.
E-mail address: lortega@ahn.org (L.M. Ortega).